Here’s who stands to gain from Intarcia’s success with a type 2 diabetes pump
October 02, 2014 at 12:38 PM EDT
The success in a late stage trial of a tiny, implantable pump to manage type 2 diabetes developed by Intarcia Therapeutics stands to pay off big time for local investors RA Capital Management, The Baupost Group and Fidelity Investments...
